ArticleCancer prevention research (Philadelphia, Pa.)2011
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.
Article in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- P16 Expression in Human Breast Carcinoma and its Relationship to Clinicopathological Parameters.Advanced biomedical research · 2023Article
- Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.Breast cancer research and treatment · 2023Article
- Revisiting Epithelial Carcinogenesis.International journal of molecular sciences · 2022Article
- Investigation of p16 protein expression and its association with histopathologic parameters in breast cancer.Molecular biology research communications · 2021Article
- Gene expression signature of atypical breast hyperplasia and regulation by SFRP1.Breast cancer research : BCR · 2019Article
- CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes.Breast cancer research and treatment · 2018Article
- Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses?Cellular and molecular life sciences : CMLS · 2017Review
- Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution.Breast cancer research and treatment · 2017Article
- NanoString-based breast cancer risk prediction for women with sclerosing adenosis.Breast cancer research and treatment · 2017Article
- Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.Virchows Archiv : an international journal of pathology · 2016Article
- The role of molecular biomarkers for predicting adjacent breast cancer of Atypical Ductal Hyperplasia diagnosed on core biopsy.Cancer biomarkers : section A of Disease markers · 2016Article
- Ductal Carcinoma In Situ of the Breast.The Indian journal of surgery · 2015Review
- Stage of breast cancer progression influences cellular response to activation of the WNT/planar cell polarity pathway.Scientific reports · 2014Article
- Molecular classification of breast cancer.Virchows Archiv : an international journal of pathology · 2014Article
- Immune cell quantitation in normal breast tissue lobules with and without lobulitis.Breast cancer research and treatment · 2014Article
- Stromal biomarkers in breast cancer development and progression.Clinical & experimental metastasis · 2012Review
- Ductal carcinoma in situ of the breast: a surgical perspective.International journal of surgical oncology · 2012Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
p16, a nuclear protein encoded by the p16(INK4a) gene, is a regulator of cell-cycle regulation. Previous studies have shown that expression of p16 in tissue biopsies of patients with ductal carcinoma in situ (DCIS) is associated with increased risk of breast cancer, particularly when considered in combination with other markers such as Ki-67 and COX-2. Here, we evaluated how expression of p16 in breast tissue biopsies of women with atypical hyperplasia (AH), a putative precursor lesion to DCIS, is associated with subsequent development of cancer. p16 expression was assessed by immunohistochemistry in archival sections from 233 women with AH diagnosed at the Mayo Clinic. p16 expression in the atypical lesions was scored by percentage of positive cells and intensity of staining. We also studied coexpression of p16, with Ki-67 and COX-2, biomarkers of progression in AH. Risk factor and follow-up data were obtained via study questionnaire and medical records. Forty-seven patients (20%) developed breast cancer with a median follow-up of 14.5 years. Staining of p16 was increased in older patients relative to younger patients (P = 0.0025). Although risk of developing breast cancer was not associated with increased p16 expression, joint overexpression of Ki-67 and COX-2 was found to convey stronger risk of breast cancer in the first 10 years after diagnosis as compared with one negative marker (P < 0.01). However, the addition of p16 levels did not strengthen this association. p16 overexpression, either alone or in combination with COX-2 and Ki-67, does not significantly stratify breast cancer risk in women with AH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.